StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Centers for Vulvovaginal Disorders, DC, Washington D.C., District of Columbia

Centers for Vulvovaginal Disorders, FL, Tampa, Florida

Centers for Vulvovaginal Disorders, NY, New York, New York